Metastatic rectal cancer

Thorvardur R. Halfdanarson, Joleen M. Hubbard

Research output: Chapter in Book/Report/Conference proceedingChapter


Colorectal cancer is a common malignancy and up to 20 % of patients have metastases at diagnosis and up to 50 % of those with localized disease will suffer a recurrence. The problem of metastatic colorectal cancer is therefore substantial. Most patients with metastatic colorectal cancer are treated with palliative intent where the treatment is aimed at prolonging survival and maintaining the quality of life of patients for as long as possible. There have been major advances in the management of metastatic colorectal cancer in the last decade with the advent of multiple new agents for systemic therapy, both cytotoxic drugs and biological agents such as VEGF and EGFR inhibitors. As a result, the overall survival of patients with metastatic colorectal cancer has improved markedly. Furthermore, biomarkers are assuming a larger role in the management of and allow for more tailored management of individual patients.

Original languageEnglish (US)
Title of host publicationModern Management of Cancer of the Rectum
PublisherSpringer-Verlag London Ltd
Number of pages24
ISBN (Electronic)9781447166092
ISBN (Print)9781447166085
StatePublished - Jan 1 2015


  • 5-fluorouracil
  • Aflibercept
  • Bevacizumab
  • Biological therapy
  • Capecitabine
  • Cetuximab
  • Chemotherapy
  • Colorectal cancer
  • Irinotecan
  • Metastases
  • Oxaliplatin
  • Panitumumab
  • RAS mutations

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Metastatic rectal cancer'. Together they form a unique fingerprint.

Cite this